




10th May,2017



		4
Nifty		-
Open	9337.35	-
High	9338.95	
Low	9307.70	
Close	9316.85	
% Chg	0.03%	



29977.50
30017.82
29911.44
29933.25
0.02%

STOCK INDICES			
SENSEX	29933.25	0.02%	
NIFTY	9316.85	0.03%	
BSE MIDCAP	14821.13	0.19%	
CNX MIDCAP	18255.50	0.51%	
Nifty Top Gainer			
IOC	442.45	428.50	3.26
LT	1745.00	1709.60	2.07
ADANIPORTS	347.25	340.50	1.98
AXISBANK	519.05	511.20	1.54
WIPRO	508.55	502.30	1.24
Nifty Top Looser	Closing	Previous	Change
HEROMOTOCO	3,280.00	3,401.25	-3.56
IBULHSGFIN	1,086.90	1,119.95	-2.95
LUPIN	1,255.00	1,279.80	-1.94
BHARTIARTL	345.70	351.30	-1.59
AUROPHARMA	595.80	604.65	-1.46
Cogurities Dan in T	rada		

#### Securities Ban in Trade

Jake-Up

ADANIENT BHARATFIN HDIL IRB JSWENERGY KTKBANK SYNDIBANK

**UJJIVAN** 

### Domestic-

### Corporate-

- Jubilant Life Sciences: The company on Tuesday said it has restarted its manufacturing operations at Gajraula in Uttar Pradesh, except distillery unit. The revenue impact of the distillery operations in FY- 2017 is not significant.
- State Bank of India: Country's largest lender SBI on Tuesday said it plans to raise funds through followon public offer and institutional placement in the current fiscal and has sought applications from merchant bankers for managing the issue.
- **Infosys:** Infosys could hand out pink slips to hundreds of mid- and senior-level employees as it carries out bi-annual performance review amid a challenging business environment. The development comes at a time when its peers Wipro and Cognizant are taking similar measures to control costs.
- **Piramal Enterprises:** The company is planning to raise up to Rs 4,000 crore by selling shares to institutional investors as the diversified company looks to fuel growth in its financial services business, according to two people familiar with the matter.
- **Lupin:** Drug major Lupin clarified to the media news after market hours on Tuesday. The company said that recently its Aurangabad facility underwent an inspection by the US Food and Drug Administration (USFDA). The inspection was completed on April 26, 2017, subsequent to which, the USFDA issued Form 483 citing eight observations. The company is in the midst of putting together a response to address the observations.
- Atul Ltd: Atul said that the joint venture agreements for the partnership with Akzo Nobel Chemicals International BV (Akzo) have been executed between the company, its affiliates and Akzo.

## Comments:

The benchmark indices settled flat on Tuesday as investors booked profits in recent outperformers such as Ambuja Cements and ACC while banks erased gains from the previous session's rally.

Wallfort Research Page 1 of 2



# Wallfort Research is also available on Bloomberg < Code WFSR>

Disclaimer: This document has been prepared by the Research Division of Wallfort Financial Services Ltd. Mumbai, India (WFSL) and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of WFSL. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security. The information contained in this report has been obtained from sources that are considered to be reliable. However, WFSL has not independently verified the accuracy or completeness of the same. Neither WFSL nor any of its affiliates, its directors or its employees accept any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein. Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipient's particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor. Either WFSL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal or engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication. We may from time to time solicit or perform investment banking or other services for any company mentioned in this document.

Disclosure: Wallfort Financial Services Ltd. / its affiliates entities / employees may hold a position in the stock(s) recommended above.

Wallfort Research Page 2 of 2